

28 October 2025

Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

# **Q1 FY26 Quarterly Activities Report**

**Melbourne, Victoria** | Alcidion Group Limited (ASX: ALC) (Alcidion or the Company) has today released its Appendix 4C and Quarterly Activities Report for the quarter ended 30 September 2025 (Q1 FY26).

# **Highlights:**

- Q1 new TCV sales of \$8.2M
  - \$6.8M expansion to North Cumbria contract with Alcidion to deliver MediViewer document management solution from partner Mizaic
  - Several existing contract renewals
- Q1 FY26 operating cash outflow of \$0.6M, a material improvement vs. \$3.9M outflow in Q1 FY25
  - Quarterly cash receipts of \$8.4M vs. \$6.3M pcp (prior corresponding period)
- As of 30 September 2025, FY26 contracted (sold and renewal) revenue of \$36.3M, with new sales
  expected to increase this figure over the remaining 9 months of FY26
- Cash balance of \$16.4M and no debt as of 30 September 2025
- Reconfirming FY26 guidance for positive EBITDA and operating cashflow

**Alcidion CEO and Managing Director, Kate Quirke said**: "Alcidion had a pleasing 1<sup>st</sup> quarter that sets the company up with strong foundations for the remainder of the year. We delivered a material improvement on the same period last year and financially we are well positioned heading into future quarters which historically have stronger cash receipts due to the annual billing cycle of several major customers, coupled with typical seasonal patterns of procurement in our key markets."

"During the period we continued to expand our relationship with North Cumbria by partnering with Mizaic, a provider of document management solutions. This contract expansion not only highlights Alcidion's unique ability to interoperate with a variety of third-party vendors but also validates the progressive expansion opportunity with existing customers as their requirements evolve and budgets become available. Including the Mizaic expansion, the combined TCV for delivering a modular EPR solution to North Cumbria is now more than \$45M."

"Our delivery teams have been working hard to support new deployments, with Miya Emergency deployed successfully at University Hospitals Southampton NHS Foundation Trust (UHS), and Miya Flow is now live at North Adelaide Local Health Network (NALHN). During the first week of live operations at UHS, the hospital experienced record levels of patients, at one point efficiently managing over 200 concurrent patients in the Emergency department. At NALHN, our electronic journey boards have replaced whiteboards across both Lyell McEwen and Modbury Hospitals, and our bed management and operations centre capabilities are now in use at the NALHN Network Operations Centre."

"At the end of Q1, we have contracted and renewal revenue able to be recognised in FY26 of \$36.3M, the highest value of in-year contracted revenue as of Q1 in Alcidion's history. We are confident in the progression of several opportunities with the scale of our referenceabilty across multiple markets driving continued inbound interest in our products."

1. Annual Recurring Revenue defined as the value of Support & Maintenance (S&M), hosting and/or license revenue that is contracted to be billed annually. This does not include multi-year capital licenses paid during the year or which will reoccur again upon a future contract renewal. ARR is a measure of the future annualised revenue as at a point in time




# **Financial Update**

Alcidion generated Q1 new sales of \$8.2M of which approximately 92% is recurring product revenue and 8% is non-recurring services (primarily product implementation) revenue.

Cash receipts from customers in Q1 were \$8.4M leading to an operating cash outflow of \$0.6M, an improvement of \$3.2M when compared with Q1 FY25.

Staff cash costs remain in-line with Q4 FY25 and as previously disclosed include the remaining 50% payment of STI staff bonuses relating to the FY25 year.



As noted in item 6 of the Company's Appendix 4C, payments made to related parties and their associates totalled \$0.33M for the quarter. These payments relate solely to Director's remuneration.

#### Outlook

As of 30 September 2025, Alcidion has FY26 contracted (sold and renewal) revenue of \$36.3M, with new sales expected to increase this figure over the remaining 9 months of the year.

Alcidion reconfirms FY26 guidance to deliver positive EBITDA and operating cashflow, with the quantum dependent on the timing of contracts progressing through the procurement stages.

As of 30 September 2025, the cash balance was \$16.4M with no debt.

### **Investor Webcast**

Alcidion Group Managing Director Kate Quirke will host a webcast with investors via Zoom on Tuesday, 28 October 2025 at 10:30am Australian Eastern Daylight Time (AEDT).

To register for the webcast, please follow this link:

https://us02web.zoom.us/webinar/register/WN 6B0WQBaJQyCUJiV1WQyrOw

Registered participants will receive an email containing the Zoom access link and phone dial-in details.

#### #### ENDS ####

Authorised for ASX release by the Board of Directors of Alcidion Group Limited.



For further information, please contact:

#### **Investor Relations**

investor@alcidion.com

#### **About Alcidion**

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2025

# **Appendix 4C**

# Quarterly cash flow report for entities subject to Listing Rule 4.7B

# Name of entity

ALCIDION GROUP LIMITED

# ABN Quarter ended ("current quarter")

77 143 142 410 30 September 2025

Consolidated statement of cash flows		ted statement of cash flows Current quarter \$A'000	
1.	Cash flows from operating activities		
1.1	Receipts from customers	8,431	8,431
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(951)	(951)
	(c) advertising and marketing	(164)	(164)
	(d) leased assets	-	-
	(e) staff costs	(6,730)	(6,730)
	(f) administration and corporate costs	(1,112)	(1,112)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	52	52
1.5	Interest and other costs of finance paid	(17)	(17)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other – GST/VAT received/(paid)	(156)	(156)
1.9	Net cash from / (used in) operating activities	(647)	(647)

2.	Cas	sh flows from investing activities		
2.1	Payı	ments to acquire or for:		
	(g)	entities	-	-
	(h)	businesses	-	-
	(i)	property, plant and equipment	(7)	(7)
	(j)	investments	-	-
	(k)	intellectual property	-	-
	(I)	other non-current assets	-	-

ASX Listing Rules Appendix 4C (17/07/20)

Page 1

Con	solidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(7)	(7)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payment for principal portion of lease liabilities)	(185)	(185)
3.10	Net cash from / (used in) financing activities	(185)	(185)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	17,697	17,697
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(647)	(647)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(7)	(7)

Con	solidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(185)	(185)
4.5	Effect of movement in exchange rates on cash held	(429)	(429)
4.6	Cash and cash equivalents at end of period	16,429	16,429

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	15,977	17,376
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (TDs)	452	321
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	16,429	17,697

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	331
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.		

ources of finance available to the entity.	\$A'000	\$A'000
oan facilities	-	-
Credit standby arrangements	-	-
Other (please specify)	150	21
otal financing facilities	150	21
Inused financing facilities available at qu	arter end	129
	Credit standby arrangements Other (please specify) Otal financing facilities	oan facilities - Credit standby arrangements - Other (please specify) 150

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

WBC corporate credit card facility secured against cash deposits; interest charged at 14.25% on overdue accounts

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(647)
8.2	Cash and cash equivalents at quarter end (item 4.6)	16,429
8.3	Unused finance facilities available at quarter end (item 7.5)	129
8.4	Total available funding (item 8.2 + item 8.3)	16,558
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	26
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item figure for the estimated quarters of funding available must be included in item 8.5.	8.5 as "N/A". Otherwise, a

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

# Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 October 2025

Authorised by: The Board of Directors

#### Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

ASX Listing Rules Appendix 4C (17/07/20)